期刊
KIDNEY INTERNATIONAL
卷 95, 期 4, 页码 747-749出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.kint.2018.12.006
关键词
-
资金
- French National Research Agency Fighting Heart Failure [ANR-15-RHU-0004]
- French Programme Investissements d'Avenir project Lorraine Universite d'ExcellenceGEENAGE programs [ANR-15-IDEX-04-LUE]
- CHRU de Brest
- French Programme Hospitalier de Recherche Clinique (PHRC-N)
The Spin-D (Safety and Cardiovascular Efficacy of Spironolactone in Dialysis-Dependent End-Stage Renal Disease) and MiREnDa (Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease) trials taken together provide the reassuring demonstration that up to 25 mg/d spironolactone is reasonably safe, provided maintenance hemodialysis patients are properly monitored and investigators use a per-protocol therapeutic algorithm to manage hyperkalemia. These results should encourage and reassure the investigators of the 2 currently ongoing, large, international, major-outcome clinical trials, both of which are using spironolactone up to 25 mg/d: ACHIEVE (Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease trial; NCT03020303) and ALCHEMIST (ALdosterone antagonist Chronic HEModialysis Interventional Survival Trial; NCT01848639).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据